Divi’s Laboratories, ranked as India’s second-largest pharmaceutical company by market capitalization, is anticipated to unveil strong financial results for the April-June quarter. Analysts forecast a notable 14-18% surge in revenue, coupled with robust margin expansion during this period.
Industry experts from BNP Paribas, Kotak Securities, and Nuvama project a first-quarter revenue growth ranging from 14% to 18% year-on-year for Divi’s Laboratories. Profit after tax is expected to witness a significant 34% increase compared to the previous year. The company’s custom synthesis segment is likely to maintain its momentum, with a projected 23% growth year-on-year for the April-June quarter.
Divi’s generic active pharmaceutical ingredients (API) business is anticipated to grow by 13% year-on-year, offset by a slight decline of 4% from the preceding quarter. The firm is expected to witness substantial margin expansion in terms of earnings before interest, taxes, depreciation, and amortization (EBITDA), with estimated margins varying between 33.1% and 34% according to different brokerage reports.
Despite facing challenges in cost management due to regulatory compliance requirements over the past decade, Divi’s Laboratories has managed to sustain a competitive edge, particularly in its generics business. The company’s EBITDA margin is projected to reach 33.7% in FY26E and 35.4% in FY27E, demonstrating a positive outlook for future growth potential.
Divi’s management has set forth ambitious revenue growth targets for the current financial year, aiming for double-digit expansion. While the company experienced a slight slowdown in revenue growth during the fourth quarter of the previous fiscal year, its net profit surged by 23% and EBITDA by 21.2% year-on-year. Notably, Divi’s revenue has shown consistent growth trends over the past decade.
The company’s strategic investments in expanding its custom synthesis business and peptide capabilities align with the growing global demand for peptide-based therapies. By signing key agreements and investing in cutting-edge synthesis technologies, Divi’s Laboratories is positioning itself for sustained growth and innovation in the evolving therapeutic landscape.
Despite its promising performance, concerns around the high valuations of Divi’s Laboratories persist. Analysts caution that the stock valuation has surpassed reasonable levels, partly fueled by expectations surrounding China+1 strategies and the demand for peptide-based therapies. Maintaining a balance between growth expectations and valuations will be crucial for Divi’s Laboratories to navigate the competitive pharmaceutical landscape effectively.
Key Takeaways:
– Divi’s Laboratories is expected to showcase robust revenue growth and margin expansion in the April-June quarter.
– Strategic investments in custom synthesis and peptide capabilities are driving innovation and growth for the company.
– Analysts remain cautious about the high valuations of Divi’s Laboratories, emphasizing the need for a balanced growth strategy.
– The company’s consistent revenue growth trends and ambitious targets for the current fiscal year highlight its resilience and strategic vision.
Tags: regulatory
Read more on livemint.com